May72021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit May 7, 2021
May62021 Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 May 6, 2021
May52021 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development May 5, 2021
Apr262021 Anavex Life Sciences to Present at the B. Riley Securities’ Virtual Neuroscience Conference April 26, 2021
Apr122021 Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board for its Phase 2/3 Trials of ANAVEX®2-73 in Patients with Rett Syndrome April 12, 2021
Apr82021 Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference April 8, 2021
Apr72021 Anavex Life Sciences Announces Participation at Upcoming World EPA – Evidence, Pricing and Access – Congress 2021 April 7, 2021
Mar312021 Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease March 31, 2021
Mar162021 Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy” March 16, 2021
Mar42021 Anavex Life Sciences to Present at the H.C. Wainwright Global Life Sciences Conference March 4, 2021
Feb222021 Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day® February 22, 2021
Feb192021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit – West Coast February 19, 2021
